Education
About Us
Working with TipRanks
Follow Us
APONTIS PHARMA AG (DE:APPH)
XETRA:APPH
APPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range€6.30 - €12.35
Previous CloseN/A
Volume747.00
Average Volume (3M)1.30K
Market Cap
€95.63M
Enterprise Value€68.26M
Total Cash (Recent Filing)€29.84M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)124.3
Beta0.15
Next Earnings
May 13, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding8,500,000
10 Day Avg. Volume213
30 Day Avg. Volume1,299
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.66
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.00Price Target Upside-11.11% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering0
---
APPH FAQ
What was APONTIS PHARMA AG’s price range in the past 12 months?
APONTIS PHARMA AG lowest stock price was €6.30 and its highest was €12.35 in the past 12 months.
What is APONTIS PHARMA AG’s market cap?
APONTIS PHARMA AG’s market cap is €95.63M.
When is APONTIS PHARMA AG’s upcoming earnings report date?
APONTIS PHARMA AG’s upcoming earnings report date is May 13, 2025 which is in 20 days.
How were APONTIS PHARMA AG’s earnings last quarter?
APONTIS PHARMA AG released its earnings results on Mar 31, 2025. The company reported €0.006 earnings per share for the quarter, beating the consensus estimate of N/A by €0.006.
Is APONTIS PHARMA AG overvalued?
According to Wall Street analysts APONTIS PHARMA AG’s price is currently Overvalued.
Does APONTIS PHARMA AG pay dividends?
APONTIS PHARMA AG does not currently pay dividends.
What is APONTIS PHARMA AG’s EPS estimate?
APONTIS PHARMA AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does APONTIS PHARMA AG have?
APONTIS PHARMA AG has 8,500,000 shares outstanding.
What happened to APONTIS PHARMA AG’s price movement after its last earnings report?
APONTIS PHARMA AG reported an EPS of €0.006 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.431%.
Which hedge fund is a major shareholder of APONTIS PHARMA AG?
Currently, no hedge funds are holding shares in DE:APPH
---
APONTIS PHARMA AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
34.89%
12-Months-Change
Fundamentals
Return on Equity
2.46%
Trailing 12-Months
Asset Growth
-22.77%
Trailing 12-Months
Company Description
APONTIS PHARMA AG
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.
---
APPH Stock 12 Month Forecast
Average Price Target
€10.00
▼(-11.11% Downside)
Technical Analysis
Best Analysts Covering APPH
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+17.29%
reiterated a sell rating 5 months ago
Copying Christian Ehmann's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +17.29% per trade.
---